Evidence Explorer · MS-N265 · Acupuncture · symptom support during autologous hematopoietic cell transplant · Appraised November 7, 2026
In a sham-controlled trial during high-dose melphalan and autologous transplant, acupuncture did not significantly improve the prespecified overall symptom-burden or interference outcomes, although several day-15 symptoms favored acupuncture.
Evidence at a glance
- Benefit signal: Primary overall symptom outcomes were negative; nausea, appetite and drowsiness signals were secondary and need confirmation.
- Certainty: Low. The trial was small, used multiple secondary comparisons and was not powered for individual symptoms.
- Risk context: Few attributable adverse events were reported, but transplant-related neutropenia, thrombocytopenia and line care make timing and sterile technique especially important.
- Cancer-control relevance: This is supportive-care evidence. It does not test tumor response, recurrence or survival.
What was studied
Sixty adults with multiple myeloma receiving high-dose melphalan followed by autologous hematopoietic cell transplantation were randomized to true or sham acupuncture once daily for five days beginning the day after chemotherapy. Participants and clinical evaluators were blinded; acupuncturists were not. The primary outcome was MD Anderson Symptom Inventory burden during transplant and at days 15 and 30.
What the study found
True acupuncture did not significantly reduce overall core symptom scores or interference during transplant (p=.4 and .3), at day 15 (p=.10 and .3) or day 30 (p=.2 and .4). At day 15, nausea (p=.042), lack of appetite (p=.025) and drowsiness (p=.010) favored true acupuncture. Sham recipients were more likely to increase pain medication use (OR 5.31; p=.017).
What this does not establish
Secondary symptom findings do not overturn the negative primary outcomes and may reflect multiple testing. The trial does not show faster engraftment, fewer infections, shorter hospitalization or improved myeloma control.
Safety and practical context
Any needling during transplant must be approved by the transplant team and adapted to platelet and neutrophil counts, skin integrity and infection-control policy. Fever, bleeding or line complications require standard medical care, not acupuncture.
Questions for the care team
- Does the transplant program permit acupuncture during nadir, and what blood-count thresholds apply?
- Which symptoms are most important to target, and what standard antiemetic or pain options remain available?
- How will infection-control technique and post-needling bleeding be monitored?
Sources and identifiers
Funding and conflicts: The report lists NCI support. Several investigators disclosed relationships with pharmaceutical companies; the remaining authors reported no competing financial interests.
Source access and dates: PubMed record and open full text were appraised. Trial registration: NCT01811862. Sources checked November 7, 2026. Last literature search November 7, 2026.
Educational evidence summary, not individualized medical advice. These approaches should complement—not replace—oncology, rehabilitation, palliative or symptom-directed care.
